From my experience of several AHA meetings, I agree it's extremely unlikely anything of great importance would be presented as a poster. There could be a lot of interesting data for researchers to chew over, but nothing in my view that is going to change clinical practice.

I presume the investigators involved in the trial will include big names in CKD and cognitive function, as well as in CVD. If there are important results to present on CKD and/or cognitive function, my expectation is that these academics will want to present them at the meetings in their particular specialty, not at the AHA.  There are two reasons for this. First, they want to have maximum exposure among their colleagues around the world to deliver the message. Second, the specialist meetings enable data to be given the highest quality discussion and assessment by other investigators. All the top cognitive and CKD people are unlikely to be at the AHA.

You also have to keep in mind that 8 minutes is not long to give a slide presentation that has to include details of the investigators, background to the study, the nature of the drug, the design of the trial, the characteristics of the participants, results, and conclusions. The presenter will have only a few slides on the results, and I presume these will include 3 point MACE, 5 point MACE, RRR, cardiovascular mortality, total mortality, adverse effects. So squeezing in results on CKD, ALP, and/or cognitive function might be impossible even they wanted to!

So, my expectation is that the AHA presentation will focus on CVD, period.

All just my opinion of course. We'll know pretty soon!